Market revenue in 2023 | USD 452.3 million |
Market revenue in 2030 | USD 1,190.5 million |
Growth rate | 14.8% (CAGR from 2023 to 2030) |
Largest segment | Phase ii |
Fastest growing segment | Phase IV |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 45.35% in 2023. Horizon Databook has segmented the Spain cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Spain is ranked as one of the top countries in terms of number of clinical trials performed. The country is a highly desirable location for conducting clinical trials as it is known as an innovation and knowledge hub with highly coordinated research centers, clinical trials specialized hospitals, and experienced investigators.
Further, the Cell and Gene Therapy Clinical Trials in the early stages are growing progressively in Spain due to the high scientific level of the professionals in the Spanish National Health Systems & the commitment of the pharmaceutical firm to the R&D. The Cell and Gene Therapy Clinical Trials in the early stages accounted for 51.4% of the total market.
This is largely due to the new Royal Decree of Cell and Gene Therapy Clinical Trials that came into force in 2018 that have created a much more favorable environment for R&D of new medicines.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain cell and gene therapy clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Spain cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account